Can As2O3 improve the prognosis of childhood acute promyelocytic leukemia?--A single center experience.
- Author:
Yi-fei CHENG
1
;
Le-ping ZHANG
;
Ai-dong LU
;
Gui-lan LIU
;
Bin WANG
;
Cai-feng LIU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Arsenicals; administration & dosage; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; drug therapy; genetics; Male; Oncogene Proteins, Fusion; genetics; Oxides; administration & dosage; Prognosis; Retrospective Studies; Treatment Outcome; Tretinoin; administration & dosage
- From: Chinese Journal of Hematology 2008;29(7):454-458
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo retrospectively analyze the treatment outcomes and side effects of childhood acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) or ATRA + arsenic trioxide (As2O3).
METHODSFrom 1992 to 2006, 45 patients with newly diagnosed APL were enrolled. All of them were PML-RAR alpha positive. 24 patients were induced with ATRA (group A) and 21 with ATRA + As2O3 (group B). The remission rate and side effects were observed.
RESULTS1) 19 (79.2%) patients in group A achieved CR, while 21(100%) patients in group B achieved CR. The CR rate in group A was lower than that in group B (P=0.027). 2) The recovery time of coagulation parameters and PLT count in group B was shorter than that in group A. 3) The overall survival (OS) and event-free survival(EFS) in group A were 77.8% and 66.9% at 41 months of follow-up, and in group B were 100% and 100% respectively at 34 months of followup. Group A had a significant lower EFS (P=0.0357)than group B. 4) The time of PML-RAR alpha fusion gene converting to negative in group A was longer (P=0.026) than that in group B.
CONCLUSIONSATRA + As2O3 for patients with newly diagnosed childhood APL is a feasible treatment with higher CR rate, less side effects and longer long-term survival.
